Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model

Details Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model

2008-03-27

arxiv.org/abs/0803.3919v1

Annals of Applied Statistics 2008, Vol. 2, No. 1, 386-407

Statistics

Applications

Published in at http://dx.doi.org/10.1214/07-AOAS132 the Annals of Applied Statistics (http://www.imstat.org/aoas/) by the Ins

Scientific paper

10.1214/07-AOAS132

Assessing immune responses to study vaccines as surrogates of protection plays a central role in vaccine clinical trials. Motivated by three ongoing or pending HIV vaccine efficacy trials, we consider such surrogate endpoint assessment in a randomized placebo-controlled trial with case-cohort sampling of immune responses and a time to event endpoint. Based on the principal surrogate definition under the principal stratification framework proposed by Frangakis and Rubin [Biometrics 58 (2002) 21--29] and adapted by Gilbert and Hudgens (2006), we introduce estimands that measure the value of an immune response as a surrogate of protection in the context of the Cox proportional hazards model. The estimands are not identified because the immune response to vaccine is not measured in placebo recipients. We formulate the problem as a Cox model with missing covariates, and employ novel trial designs for predicting the missing immune responses and thereby identifying the estimands. The first design utilizes information from baseline predictors of the immune response, and bridges their relationship in the vaccine recipients to the placebo recipients. The second design provides a validation set for the unmeasured immune responses of uninfected placebo recipients by immunizing them with the study vaccine after trial closeout. A maximum estimated likelihood approach is proposed for estimation of the parameters. Simulated data examples are given to evaluate the proposed designs and study their properties.

Affiliated with

Also associated with

No associations

Rating

Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model does not yet have a rating. At this time, there are no reviews or comments for this scientific paper.

If you have personal experience with Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFWR-SCP-O-353959